← All trials
NCT05491811
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2022
- Primary completion
- Nov 30, 2023
- Completion date
- Dec 31, 2026
- First posted
- Aug 8, 2022
- Last posted
- Aug 8, 2022
- Enrollment
- 77
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Huazhong University of Science and TechnologyCollaborator
- Hebei UniversityCollaborator
- Harbin Medical UniversityCollaborator
- Huai'an First People's HospitalCollaborator
- Nanjing Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Dalian Medical UniversityCollaborator
- Soochow UniversityCollaborator
- Zhejiang UniversityCollaborator
- Sun Yat-Sen UniversityReponsible party - principal investigator
- Jiangsu Cancer Institute & HospitalCollaborator
- Shenyang Chest HospitalCollaborator
- Handan Central HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.